Travere Therapeutics (TVTX) Non-Current Assets (2013 - 2026)
Travere Therapeutics' (TVTX) quarterly Non-Current Assets came in at $162.5 million in Q1 2026, down 6.94% YoY from $174.6 million in Q1 2025, and down 3.05% on a QoQ basis from $167.6 million in Q4 2025.
Travere Therapeutics (TVTX) Non-Current Assets (2013 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 14 years of Non-Current Assets data on file, last reported at $162.5 million in Q1 2026.
- Quarterly Non-Current Assets fell 6.94% year-over-year to $162.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $673.3 million (down 5.68% YoY) and the FY2025 annual result came in at $167.6 million, down 5.52% from the prior year.
- Non-Current Assets eased to $162.5 million in Q1 2026, from $167.6 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $203.3 million in Q1 2023 to a low of $146.6 million in Q3 2023.
- A 5-year average of $179.6 million and a median of $179.7 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets fell 23.39% — and 2024, when it increased 22.54%.
- Tracing TVTX's Non-Current Assets over 5 years: stood at $186.1 million in 2022, then declined by 7.53% to $172.1 million in 2023, then advanced by 3.07% to $177.4 million in 2024, then declined by 5.52% to $167.6 million in 2025, then dropped by 3.05% to $162.5 million in 2026.
- The last three Non-Current Assets figures came in at $162.5 million (Q1 2026), $167.6 million (Q4 2025), and $167.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 184.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 184.22 Mn |
| Mar 31, 2026 | 162.51 Mn |
| Dec 31, 2025 | 167.63 Mn |
| Sep 30, 2025 | 167.47 Mn |
| Jun 30, 2025 | 175.74 Mn |
| Mar 31, 2025 | 174.63 Mn |
| Dec 31, 2024 | 177.42 Mn |
| Sep 30, 2024 | 179.67 Mn |
| Jun 30, 2024 | 182.14 Mn |
| Mar 31, 2024 | 182.47 Mn |
| Dec 31, 2023 | 172.14 Mn |
| Sep 30, 2023 | 146.62 Mn |
| Jun 30, 2023 | 194.37 Mn |
| Mar 31, 2023 | 203.33 Mn |
| Dec 31, 2022 | 186.15 Mn |
| Sep 30, 2022 | 191.37 Mn |
| Jun 30, 2022 | 192.72 Mn |
| Mar 31, 2022 | 197.31 Mn |
| Dec 31, 2021 | 193.81 Mn |
| Sep 30, 2021 | 196.00 Mn |